| Treatment of Actinic Keratoses With 5% Topical Imiquimod: A Multicenter Prospective Observational Study from 93 Austrian Office-based Dermatologists. | |
| | |
MedLine Citation:
|
PMID: 22527424 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Background: While randomized, controlled trials have generated information about the safety and efficacy of imiquimod 5% cream in the treatment of actinic keratosis, still very little is known about the challenges and pitfalls of this therapy in the daily clinical routine. Objective: To mirror the full picture of the actinic keratosis imiquimod routine therapy, ie, patient profile, in-therapy decisions, tolerability, and satisfaction. Methods: The present observational, multicenter study included 463 patients from the offices of 93 non-hospital based Austrian dermatologists. Inclusion was solely based on the treatment decision of the dermatologist and the patient's will to participate. There were no specific interventions except suggested time points of visits with pre-defined documentation forms. Results: The typical actinic keratosis patient was a male, aged 74 years, with a disease history of 5.7±5.3 years, who presented with 8.4±8.0 multiple pre-treated lesions at the face. More than 95% of the patients developed therapeutic skin responses (dominated by erythema and crusting), which led to a significant reduction of lesions from baseline to the end of the therapy. Notably, one-third of those patients prone to a second therapeutic course were submitted to another form of treatment. Post-imiquimod therapy comprised of antibiotic creams, topical steroids, and numerous emollients. Patients and dermatologists reported high satisfaction with the therapy including the cosmetic outcome. Conclusion: Our data show the high need for experience at the dermatologist side and information at the patient side. Moreover, the method of treatment for imiquimod-related skin reactions definitively asks for standardization. The study was registered at ClinicalTrials.gov (NCT01151956). Decision by ClinicalTrials.gov: Federal University Teaching Hospital, Feldkirch, Austria Protocol Record OBIMQ465-AK-08, Imiquimod and actinic keratoses: an observational study. J Drugs Dermatol. 2012;11(5):574-578. |
| | |
Authors:
|
Robert Strohal; Helmut Kerl; Lydia Schuster |
Related Documents
:
|
3477124 - Low-dose cytosine arabinoside (ld-ara c) treatment in dysmyelopoietic syndromes (dmps) ... 3456194 - Ph1-negative chronic granulocytic leukemia: a nonentity. 535124 - Cardiomyopathy in leukemia, with reference to rubidomycin cardiotoxicity. 15956284 - In vitro sensitivity to imatinib-induced inhibition of abl kinase activity is predictiv... 11208674 - Serial intravascular ultrasound analysis of the impact of lesion length on the efficacy... 2802364 - Detection of pneumonia by auscultation of the lungs in the lateral decubitus positions. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of drugs in dermatology : JDD Volume: 11 ISSN: 1545-9616 ISO Abbreviation: J Drugs Dermatol Publication Date: 2012 May |
Date Detail:
|
Created Date: 2012-04-24 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101160020 Medline TA: J Drugs Dermatol Country: United States |
Other Details:
|
Languages: eng Pagination: 574-8 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Origin of the synchronicity in bond formation in polar Diels-Alder reactions: an ELF analysis of the...
Next Document: Trends in Primary Skin Cancer Prevention Among US Hispanics: A Systematic Review.